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Abstract
Background: This systematic review and meta-analysis aims at assessing the composition and performance of care
management models evaluated in the last decade and their impact on patient important outcomes.
Methods: A comprehensive literature search of electronic bibliographic databases was performed to identify care
management trials in type 2 diabetes. Random effects meta-analysis was used when feasible to pool outcome
measures.
Results: Fifty-two studies were eligible. Most commonly reported were surrogate outcomes (such as HbA1c and
LDL), followed by process measures (clinic visit or testing frequency). Less frequently reported were quality of life,
patient satisfaction, self-care, and healthcare utilization. Most care management modalities were carved out from
primary care. Meta-analysis demonstrated a statistically significant but trivial reduction of HbA1c (weighted
difference in means -0.21%, 95% confidence interval -0.40 to -0.03, p < .03) and LDL-cholesterol (weighted
difference in means -3.38 mg/dL, 95% confidence interval -6.27 to -0.49, p < .02).
Conclusions: Most care management programs for patients with type 2 diabetes are ‘carved-out’, accomplish
limited effects on metabolic outcomes, and have unknown effects on patient important outcomes. Comparative
effectiveness research of different models of care management is needed to inform the design of medical homes
for patients with chronic conditions.
Keywords: Chronic Care: disease management/care management, Endocrinology: diabetes, Evidence-based medi-
cine/critical review of evidence
Background
Chronic care delivery continues to represent a challenge
to the healthcare system. New ways to deliver and man-
age care for patients with chronic conditions such as type
2 diabetes emerged in the late 90s, notably the Chronic
Care Model [1]. In 2003, a revision formalized the need
for care management [2]. Since then, many approaches
have emerged to implement the Chronic Care Model,
including those emphasizing the components of self
management support and links to community resources.
However, many care management models are offered in
a carved-out approach- not integrated with the rest of
the patients’ care, and their effectiveness despite their
popularity remains unknown. Care management pro-
grams in chronic diseases such as diabetes, congestive
heart failure and asthma can be associated with reduced
length of hospitalization and medical costs and increased
proportion of patients receiving appropriate medications
and tests [3].
We conducted a systematic review and meta-analysis of
recent controlled trials to summarize the emerging evi-
dence of comparative effectiveness of care management
modalities applied to the care of patients with type 2 dia-
betes across pertinent outcomes. Our focus on the last
decade and on type 2 diabetes stems from the need to
account for the evolving role of care management and to
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reflect advances in disease management that have favored
type 2 diabetes.
Research design and methods
This report adheres to the preferred reporting items for
systematic reviews and meta-analyses statement (the
PRISMA statement) [4].
Literature search strategy
A comprehensive search of several databases (from 1/1/
2000 through 9/21/2011) was designed and conducted
by a reference librarian with input from the study’s prin-
cipal investigator. The databases included Ovid Medline
In-Process & Other Non-Indexed Citations, Ovid MED-
LINE, Ovid EMBASE, Ovid Current Contents, Ovid
Cochrane Central Register of Controlled Trials, Ovid
Cochrane Database of Systematic Reviews, and EBSCO
Cumulative Index to Nursing and Allied Health Litera-
ture. Controlled vocabulary supplemented with key-
words was used to define the concept areas, diabetes,
care management, and treatment outcomes, as well as
to limit to controlled trials. The detailed search strategy
is available in Additional file 1: APPENDIX.
Inclusion criteria and data extraction
Three reviewers applied the following inclusion criteria to
the abstracts, with each reviewer evaluating two-thirds of
the search selections to ensure dual coverage of each
abstract: (1) Did the study test a care management inter-
vention in the US on patients with type 2 diabetes? (2)
Was the intervention group compared to a control group,
such as patients who received usual care? We included
studies in which the control group received usual care,
attention control, low intensity control interventions, or
other types of control groups.
Abstracts that were endorsed by at least one reviewer
were included after the initial screening. Citations were
kept to request full articles if they were ambiguous. After
the full articles were retrieved, each of the three reviewers
was assigned the full texts, with a duplicative process again
employed to assure dual coverage of each article. Each full
article was then evaluated on the criteria above. Endorse-
ment by two reviewers reaching consensus was necessary
for an article to be included in the final data extraction
and analysis. The agreement among reviewers was ade-
quate, (median kappa statistic = .82).
The primary aim of this systematic review is to describe
the available care models in terms of delivery method and
team composition and the outcomes they reported (pro-
cess measures such as testing and visit rates, self-care,
quality of life, patient satisfaction, healthcare utilization/




We assigned each study to a primary delivery type
“Office” if the intervention involved primarily interaction
or chart review in the medical outpatient setting; “Web”
if most interaction took place on the computer or inter-
net; “Telephone” if the intervention took place over the
phone or a pager system; and “Education” if the patient
received educational information in another setting such
as a community-based facilitated diabetes group.
Leader type
If one of the primary leaders of the intervention was dis-
cernibly a physician, we determined the trial was “Physician
Led.” If the intervention was led by a multidisciplinary
team or an individual in another type of position, such as a
diabetes nurse educator, it was categorized “Not Physician
Led.”
Study description
Study attributes were collected for each article including
a description of the enrolled participants and the study
setting; detail about the type, duration, frequency and
mode of the intervention, as well as information about
the control condition; and outcome measures.
Study quality
To assess the methodological quality of the described
studies, we noted the how randomization and allocation
concealment were conducted, whether there were
important study arm imbalances at baseline or signifi-
cant loss to follow up.
Analysis
We planned to conduct meta-analysis if data were avail-
able and appropriate for statistical pooling. For the contin-
uous outcomes of hemoglobin A1c and LDL cholesterol,
we estimated the difference in means from each study
with 95% confidence interval (CI). The difference in
means is estimated as the difference between the change
in the intervention arm and the change in the control arm
so that a negative value indicates more decline the inter-
vention arm (i.e., a negative value implies results favoring
the care management program). 95% CI that overlaps a
value of zero implies no statistically significant effect and
is analogous to a 2-tailed p value > 0.05. We pooled the
differences in means across studies using the random
effects model because of anticipated heterogeneity of the
included studies (in terms of design, populations and
interventions) [5]. The random effects model incorporates
within-study heterogeneity in the CI and produces more
conservative estimates. A priori subgroup analyses were
defined based on team composition (physician led vs not),
delivery method (web vs phone vs office vs education) and
length of follow up (≤ 1 year vs. > 1 year) and used to
explain heterogeneity by conducting a test of interaction
[6]. Heterogeneity was evaluated using the I2statistic with
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values > 50% consistent with substantial heterogeneity [7].
Meta-analysis was conducted using Comprehensive Meta-
Analysis, version 2 software [8]. When meta-analysis was
not feasible, (i.e., no reported hemoglobin A1c or LDL
values or missing measures of precision such as standard
deviations and sample sizes for two time points), we pre-
sented description of the individual studies in terms of
design, care model characteristics and conclusions.
Results
Figure 1 displays the results of our search process. The
literature search yielded 1636 abstracts from which 52
proved eligible for inclusion.
Study features
Additional file 1: Table S1 details the characteristics of
included studies (median number of enrolled patients is
266, mean study duration is 14 months; and the length
of follow-up ranged from a few weeks (49), to 5 years
(57). Studies varied by geographic area and clinical team
composition.
Criteria for patient enrollment also varied consider-
ably. Some studies focused on specific socioeconomic or
demographic characteristics [9-16], while others identi-
fied patients based on HbA1c level requirements
[12,18-26]. In 11 of the studies, enrolled patients were
included or excluded based on HbA1c levels (most typi-
cally requiring an elevated HbA1c, e.g., > 8%). A mini-
mum age, or age range, requirement was used in several
studies [9,10,13,26-30].
Forty-two of 52 were parallel randomized controlled
trials. The other nine studies followed a clustered rando-
mization of physician panels or practices, or were a
comparison of two practices. One study was a model-
based predictive trial using actual patient data; another
looked at before-after data regarding implementation of
electronic medical records. The quality of the rando-
mized trials was fair. Some of the methodological limita-
tions noted were lack of reporting of allocation
concealment and high or unclear loss to follow up rates.
Blinding care givers and patients in this evaluation was
not feasible as expected. Cluster randomized trials did
not clearly address the issue of contamination. The non-
randomized studies were in general of good quality with
adequate adjustment for confounders and apparent
baseline prognostic balance of the two study arms.
Study quality is described in Additional file 1: Table S2.
Delivery method
Office interventions were the most common, being used
in 67% of studies. Telephone and education were next,
followed by web interventions, which were only used in
seven studies (15%). Thirty-nine percent of studies
employed more than one type of intervention (office,
telephone, web or education). With the 33 office inter-
ventions, nearly half also utilized a telephone or educa-
tion intervention. Intervention delivery methods and
outcomes measured are described in Additional file 1:
Figure S1. The care management program was carved
out of primary care practice in 36/52 (69%) of the
studies.
Intervention leadership
In 15 of the 52 studies in this review, a physician can be
discerned as the leader of the intervention; in the other
36, another professional or group of professionals was
identified as facilitating the trial. All physician-led inter-
ventions were delivered in the office setting (compared
to about half of non-physician-led interventions). Two
of the physician-led interventions also had a telephone
intervention component, and another two had an educa-
tion component. The distribution of study leadership
and the method of delivery are detailed in Additional
file 1: Table S3.
Study outcomes
Figure 2 displays the reported outcomes across studies.
Seventy-three percent of studies reported more than one
outcome, with an average of two. Additional file 1:
Table S4 details the outcomes for each of the 52 studies.
The most commonly reported results were surrogate
outcomes, such as HbA1c and LDL-cholesterol. Eighty-
five percent of studies included such an outcome, and
30 of those (71%) found statistically significant results.
However, in some cases (e.g. Piette et al.) [29], the sig-
nificance reported was limited to a specific subgroup,
the high-risk group. In other cases, the authors only
Figure 1 Systematic review inclusion process.
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found significant differences between intervention and
control groups on a few of the measured surrogate out-
comes [13,26,31-36].
Studies also evaluated the impact of CM interventions
on process measures (e.g., adherence to disease monitor-
ing protocols such as getting the recommended number
of cholesterol tests in eligible populations). Fourteen
studies included at least one process outcome, and all of
these also had some type of surrogate outcome mea-
surement. Eleven of the 14 studies found some signifi-
cant results on at least one process measure, but there
were mixed results on whether those same studies also
achieved desirable surrogate outcomes. In one example,
the authors found that a pharmacist-led intervention
resulted in significant differences between intervention
and control groups on LDL measurement, retinal exam,
and foot exam rates [17].
Reductions in HbA1c level were significant, especially
among patient with the highest blood levels. In another
study, the authors did not find significant results on
changes in cholesterol or HbA1c levels, but they did get
significant results on 10 American Diabetes Association
standards of care measures–a result they surmise may
be related to small sample size and short study duration
[12]. In another example, [37] improvements in care
processes did not translate into improved surrogate out-
comes, possibly because baseline levels were relatively
good. There were also some associations between out-
comes measured.
All but one of the studies that looked at testing or visit
rates also measured surrogate outcomes. And in 70 per-
cent of cases, significant results on testing and visit rates
were associated with significant surrogate outcomes.
Self-care outcomes were included in nineteen, and ten
of these demonstrated positive change. There were a
range of self-care measures including foot exams and
self-monitoring glucose. Seven of the studies mentioned
diet or nutrition as part of the intervention.
There were seventeen studies with quality of life out-
comes (including patient satisfaction-related outcomes),
with twelve reporting at least one significant improvement.
Eight studies included some measure of health care cost or
utilization (2 with significant change), although most of
them included this as a secondary measure. The “other”
category captures outcomes such as the number of risky
prescribing events. Only two of those studies achieved sta-
tistically significant outcomes.
Physician-led studies primarily focused on surrogate
outcomes and measures like visit or testing rates. There
were less likely to include outcomes like self-care or qual-
ity of life although this comparison is not statistically sig-
nificant due to the small number of studies (Additional
file 1: Figure S2).
Meta-analysis of HbA1c and LDL outcomes
While 48 studies included some type of surrogate out-
come, only 29 provided data sufficient for meta-analysis
(seventeen of these reported complete HbA1c measures,
twelve reported complete LDL measures, and ten
reported both).
Results of the meta-analyses are shown in Figures 3 and
4. Diabetes care management interventions were asso-
ciated with a statistically significant reduction in hemoglo-
bin A1c level (weighted difference in means -0.22%; 95%
CI -0.40 to -0.04; p = 0.02). This reduction however, was
also associated with significant heterogeneity (I2 = 94%)
and is unlikely to be clinically important. The trend in
reduction in LDL associated with these programs was sta-
tistically significant (weighted difference in means - 3.38
mg/dL; 95% CI, -6.27 to -0.49; p = 0.02). This analysis was
not associated with significant heterogeneity (I2 = 27%),
and was again trivial from a clinical standpoint.
Figure 2 Types of reported outcomes.
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There was no statistically significant interaction for
length of intervention and subgroup analysis showed no
significant effect for type of intervention (office, web, tele-
phone, or education) or whether a physician played a key
role in the intervention. There was no statistically signifi-
cant interaction for the length of the intervention (defined
as > 12 months or ≤ 12 months) for either LDL (p = 0.90)
or HbA1c (p = 0.50), (See Additional file 1: Table S5).
Discussion
We conducted a systematic review of the literature eval-
uating type 2 diabetes care management interventions in
the US during the last decade. We identified 52 studies
that demonstrated heterogeneous results in terms of
improvements in process measures and paucity of data
on patient-important outcomes. We found that these
interventions were associated with some improvement
in surrogate outcomes (trivial reduction in hemoglobin
A1c and LDL cholesterol levels). We could not identify
a particular intervention type or team characteristic that
is more effective.
In the available literature, many of the disease man-
agement programs were carved out of primary care
practice. Traditionally, carve out programs were thought
Figure 3 Meta-analysis of Hemoglobin A1c.
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to provide the expertise that would be prohibitively
expensive for health plans to develop and sustain [38].
However, this trend has changed and health practices
are bringing back these programs in-house. Some of the
reasons behind this change are the availability of infor-
mation technology that enables the integration of data-
bases (prescription, claims, and laboratory data); the
potential misalignment of vendor and client interests;
insufficient transparency and insufficient evidence of
improved outcomes [38]. Moreover, integrated care is
intuitively more patient-centered and may reduce redun-
dancy. The data synthesized in this report are insuffi-
cient to recommend for or against either approach
(carved vs not). Overall, the wide variations in interven-
tion delivery methods, duration, and populations, and
the use of surrogate outcomes in the included studies,
further challenge inference and does not provide evi-
dence to support the use of these models in type 2
diabetes.
The Chronic Care Model identifies the essential ele-
ments of a health care system that encourage high-quality
chronic disease care. These elements are the community,
the health system, self-management support, delivery
system design, decision support and clinical information
systems [1,2]. The available evidence is derived from pro-
grams that do not offer all or most of these components.
Further, the studies summarized in this review do not
address the recent themes of contemporary chronic care
model (patient safety, cultural competency, care coordina-
tion, community policies and case management) [1,2].
Therefore; the efficacy of a true and practical chronic care
model in type 2 diabetes remains undetermined.
Comparison with other reviews
Pimouguet et al. conducted a systematic review and meta-
analysis focusing on HbA1c and found that care manage-
ment programs were associated with a statistically signifi-
cant reduction of -0.38 (-0.47 to -0.29) [39]. This effect
size is similar to the one detected in the current analysis
although in their analysis they pooled type 1 and type 2
diabetes studies. They found similar rates of hypoglycemia
although this outcome was poorly and non systematically
reported. Several other older reviews (1999-2006) also
focused on A1c but some found improvements in the
rates of screening for diabetic retinopathy, foot lesions,
peripheral neuropathy, and proteinuria; and on the
Figure 4 Meta-analysis of LDL-cholesterol.
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monitoring of lipid concentrations [40-42]. The current
systematic review updates the evidence base and adds to
the emerging literature on the impact, or lack thereof, of
care management on patient-important outcomes.
A recent randomized trial by McCall et al. [43]
assigned 242,417 patients with heart failure or diabetes to
eight commercial disease-management programs using
nurse-based call centers or to usual care (control). They
demonstrated that the intervention did not reduce hospi-
tal admissions or emergency room visits but led to 14
(out of 40) significant improvements in process-of-care
measures. These modest improvements came at substan-
tial cost to the Medicare program ($400 million) with no
demonstrable savings in expenditures. This trial under-
scores the apparent limits to the premise of care/disease
management for diabetes, particularly when provided
carved out of the context of primary care.
Limitations and strengths
The strength of this review stems from the focused clinical
question and comprehensive literature search. We were
more interested in the recent trend over the past decade
in diabetes care management programs and therefore did
not evaluate prior publications. We attempted to synthe-
size the evidence on outcomes that matter to patients
although meta-analyses were only possible on surrogate
laboratory outcomes. The likelihood of reporting bias and
publication bias threatens the validity of this review and its
presence is suggested by the selective reporting of out-
comes (only a small numbers of studies reported each out-
come). This review focuses on the last decade because we
aimed at providing a contemporary evaluation of the cur-
rent trends in these care models. Therefore, our conclu-
sions may be biased since relevant older publications,
summarized elsewhere, are not presented in this report.
The evaluation of publication bias was not statistically fea-
sible due to the small number of studies and the signifi-
cant heterogeneity in results across trials [44]. Lastly, we
used a consensus process to categorize study intervention
methods to allow comparisons across these methods.
However, assigning intervention methods to mutually
exclusive categories could have biased the observed effects
toward the null.
Conclusion
Best available evidence offers limited certainty about the
impact of care management for patients with type 2 dia-
betes. Based on this limited evidence, care management
improves process measures and also improves surrogate
outcomes to a trivial extent. Despite that some of the
included trials were of sufficient size and duration, there
is almost no data regarding benefits of care management
on patient-important outcomes, such as living longer
and independently, feeling better, or suffering fewer
complications.
In conclusion, the current literature does not allow the
confident endorsement of a single model or delivery
method for care management for patients with type 2
diabetes. Further research is needed to evaluate whether
existing models achieve more than the ever improving
usual care to improve outcomes of importance to
patients.
Additional material
Additional file 1: Table S1. Study Description, N = 52 [45-66].
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